Cardiac arrest (CA) with return of spontaneous circulation is associated with high mortality, exceeding 90% in out-of-hospital settings and approaching 50% in in-hospital settings. Despite management of the underlying cause of CA, patients often die from post-anoxic brain injury or from ischemia-reperfusion injury occurring after reperfusion and reoxygenation, which increases oxidative stress and leads to multi-organ failure. To date, no effective therapeutic strategy has been established in humans to limit these ischemia-reperfusion injuries. GC7 (N1-guanyl-1,7 diaminoheptane) has demonstrated a strong protective potential against ischemia reperfusion injury in rodent and porcine models, including myocardial infarction, stroke, and renal transplantation. These protective effects are attributed to the pleiotropic action of GC7 which renders cells and tissues energetically less dependent on oxygen, and reduces oxidative stress which play a major role in ischemia reperfusion injury. Degree of blood acidification and immune dysregulation may also represent parameters that GC7 could potentially influence. Although no adverse effects have been reported in these experimental models, GC7 has not yet been studied in human. Our study therefore aims to demonstrate the protective effect of GC7 on blood cells in patients after CA by evaluating oxidative stress levels, blood acidification and inflammatory profile.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Cardiac arrest as the primary reason for hospital admission
* Admission \< 48 hours
* Age ≥ 18 years
* Affiliated with a social security system
Exclusion Criteria:
* Limitation or withdrawal of life-sustaining therapies prior to study screening
* Prior cardio-vascular ischemic event (\> 24h) before cardiac arrest
* Patient deprived of liberty
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is studying GC7, a compound I'm not familiar with — can you explain how it's thought to help after cardiac arrest, and what's currently known about its safety in humans?
2The trial is measuring blood oxidative stress levels as its main outcome — does that mean it's focused on understanding what happens in the body after cardiac arrest rather than directly testing whether GC7 improves survival or recovery, and how does that affect what we'd learn from it?
3Since this trial isn't recruiting yet, there's no data available on how it's going — given my situation, would it make more sense to pursue established treatments now, and revisit this trial once it opens and more is known?
4I see this trial doesn't list a traditional phase like Phase 1 or Phase 2 — what does that mean for how much is already known about the risks and potential benefits of GC7 in cardiac arrest patients?
5Given that cardiac arrest recovery can require intense follow-up care, what would participation in this trial actually involve for me or my family in terms of time, monitoring, and medical visits once it does open?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Blood oxidative stress levels
Timeframe: at 24 hours after blood exposure to GC7